Abstract

ObjectivesTo explore baseline predictive factors for clinical remissions at 1 year after tocilizumab (TCZ) or infliximab (IFX) treatment in bio-naïve RA patients.MethodsConsecutive bio-naïve RA patients at our hospital initiating TCZ...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
FRI0023 Is Positivity of Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Associated with the Response Rate of Infliximab, Tocilizumab, and Abatacept in Treatment of Rheumatoid Arthritis?
M Sato ... K Saito
Annals of the Rheumatic Diseases | VOL. 73
M Sato, et. al.M Sato ... K Saito
01 Jun 2014
AB0589 Steroid-sparing effect of tocilizumab in the treatment of rheumatoid arthritis
S Tsuji ... Y Harada
Annals of the Rheumatic Diseases | VOL. 71
S Tsuji, et. al.S Tsuji ... Y Harada
01 Jun 2013
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).
Masataka Kuwana ... Misato Hashizume
PloS one | VOL. 10
Masataka Kuwana, et. al.Masataka Kuwana ... Misato Hashizume
23 Dec 2015
Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients.
Valeria Belvisi ... Raffaella Marocco
Frontiers in immunology | VOL. 13
Valeria Belvisi, et. al.Valeria Belvisi ... Raffaella Marocco
04 Apr 2022
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers